09:59 AM EST, 01/17/2025 (MT Newswires) -- Amgen ( AMGN ) said Friday it has received approval from the US Food and Drug Administration for Lumakras combined with Vectibix to treat adults with KRAS G12C-mutated metastatic colorectal cancer.

The approval was based on the results of a pivotal phase 3 trial showing a median progression-free survival of 5.6 months, longer than the two months on investigator's choice of care, the company said.

The study, which enrolled 160 patients, also showed an overall response rate of 26% versus 0% with investigator's choice, Amgen ( AMGN ) added.

Shares of Amgen ( AMGN ) rose 1.4% in recent Friday trading.

Price: 273.13, Change: +3.70, Percent Change: +1.37